Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Operating Leases (2019 - 2025)

Northwest Biotherapeutics' Operating Leases history spans 7 years, with the latest figure at $4.4 million for Q4 2025.

  • Quarterly results put Operating Leases at $4.4 million for Q4 2025, down 0.61% from a year ago — trailing twelve months through Dec 2025 was $4.4 million (down 0.61% YoY), and the annual figure for FY2025 was $4.4 million, down 0.61%.
  • Operating Leases for Q4 2025 was $4.4 million at Northwest Biotherapeutics, down from $4.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $5.6 million in Q1 2021 to a low of $4.1 million in Q3 2022.
  • The 5-year median for Operating Leases is $4.5 million (2023), against an average of $4.6 million.
  • The sharpest move saw Operating Leases decreased 21.91% in 2022, then increased 16.79% in 2024.
  • Year by year, Operating Leases stood at $5.2 million in 2021, then fell by 16.38% to $4.4 million in 2022, then increased by 1.92% to $4.5 million in 2023, then decreased by 0.36% to $4.4 million in 2024, then dropped by 0.61% to $4.4 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $4.4 million, $4.4 million, and $4.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.